Michael Kelly

Michael Kelly

Teknisk/Vetenskaplig/F&U Direktör på
CureDuchenne
Health Technology
Consumer Services
Finance

Profil

Michael G.
Kelly
is currently the Director at Trinds LLC since 2017 and the Chief Scientific Officer at CureDuchenne since 2011.
Previously, he worked as the President, Chief Executive Officer & Director at MyoTherix, Inc. He was also the Research Director at Amgen, Inc. from 1999 to 2000.
Additionally, he worked as a Director at NeoGenesis Pharmaceuticals, Inc. and as the Senior Vice President-Research & Development at Renovis, Inc. Dr. Kelly holds a doctorate degree from The University of Southampton and an undergraduate degree from the University of Ulster.

Aktiva positioner av Michael Kelly

FöretagPositionStart
Teknisk/Vetenskaplig/F&U Direktör 2011-12-13
Direktör/Styrelseledamot 2017-11-01

Tidigare kända positioner av Michael Kelly

FöretagPositionSlut
AMGEN INC. Teknisk/Vetenskaplig/F&U Direktör 2000-01-01
Teknisk/Vetenskaplig/F&U Direktör -
Direktör/Styrelseledamot -
Verkställande Direktör -
Se detaljerna i Michael Kellys erfarenhet

Michael Kellys utbildningar

Erfarenheter
Innehade positioner

Aktiva

Inaktiva

Börsnoterade företag

Privata företag

Relationer

42

Första gradens relationer

8

Företag kopplade till första graden

Man

Kvinna

Styrelseledamöter

Chefer

Kopplade företag

Privata företag8

Health Technology

Health Technology

Health Technology

Consumer Services

Consumer Services

Finance

Health Technology

Commercial Services

  1. Börsen
  2. Insiders
  3. Michael Kelly